Google LLC, a division of Alphabet Inc., (GOOG) (GOOGL) has announced spending an additional $1 billion on the artificial intelligence startup Anthropic, a significant OpenAI competitor,

Alphabet Inc. consistently surpasses the Rule of 40, with a current score of 42.8, showcasing an excellent balance of growth and profitability. Learn more on GOOG stock here.

Alphabet Inc. investors are experiencing a moment of vindication as the stock surged to a new high. Click here to read an analysis of GOOG stock now.

The Nasdaq Composite (NASDAQINDEX: ^IXIC) has had a monster two-year run. After gaining 43% in 2023, the index put up around 30% gains in 2024, marking one of the best-performing periods in its history.

Google (NASDAQ:GOOGL) has made an additional $1 billion investment in Anthropic, an AI startup rivaling OpenAI, according to the Financial Times. This brings Googles total investment in Anthropic to $3 billion,

In a recent development, IAC Inc. (NASDAQ:IAC), a leader in media and Internet with a market capitalization of $3.65 billion, has amended its existing services agreement with tech giant Google (NASDAQ:GOOGL).

In a remarkable display of resilience and growth, Google Inc (NASDAQ:GOOGL).'s stock has soared to a 52-week high, reaching $201.18, with a robust market capitalization of $2.41 trillion. According to InvestingPro data,

We recently published a list of 12 Best NASDAQ Stocks To Buy in 2025. In this article, we are going to take a look at where Alphabet Inc. (NASDAQ:GOOGL) stands against other best NASDAQ stocks to buy in 2025.

Google Cloud and AI integration are already working wonders in other areas of Google's ecosystem. Click here to find out why I'm rating GOOGL a hold.

Last year was fantastic for the markets in general, but the index that really stood out was the Nasdaq. The Nasdaq, heavily weighted in technology companies, surged as investors piled into the industry's hottest new area: artificial intelligence (AI) stocks.

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,

Even though Google (NASDAQ:GOOG) (NASDAQ:GOOGL) recently launched an official iOS app for its generative artificial intelligence chatbot Gemini, the tech giant is still falling behind the competition when it comes to paid subscribers,